MTOR and renal cell carcinoma: Furthermore, viaGLUD1 inhibits kidney tumor occurrence and development by suppressing the PI3K/Akt/mTOR pathway [67], while LINC00460 promotes RCC development by affecting the PI3K/AKT pathway and decreasing the phosphorylation levels of AKT and mTOR [68].